Oral Antiplatelet Therapy in ACS PLATO Primary Efficacy Outcome by Geography US vs NonUS CURE Incidence of Major Bleeding According to Aspirin Dose of Patients CHARISMA Bleeding End Points by Baseline Daily Aspirin Dose ID: 767888
Download Presentation The PPT/PDF document "Oral Antiplatelet Therapy in ACS" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Oral Antiplatelet Therapy in ACS
PLATO Primary Efficacy Outcome by Geography, US vs Non-US
CURE Incidence of Major Bleeding According to Aspirin Dose (% of Patients)
CHARISMA Bleeding End Points by Baseline Daily Aspirin Dose
CURRENT OASIS Efficacy and Bleeding by Aspirin Dose at 30 Days
Clinical Pearls Aspirin in Acute ACS
Clopidogrel in ACS
TRITON-TIMI 38
ACCOAST Differences Between Prasugrel Pretreatment and No Pretreatment
TRILOGY-ACS Incidence of Outcomes by Angiography Status
Clinical Pearls Prasugrel
PLATO Primary Efficacy End Point CV Death, MI, or Stroke
CHAMPION TRIALS
CHAMPION PHOENIX Primary Efficacy Outcomes at 48 Hours, mITT
TRA 2 o P–TIMI 50 Primary End Points in Overall Population
TRACER Primary End Point Composite of CV Death, MI, Stroke, Hospitalization for Ischemia, Urgent Revascularization
CHARISMA
MATCH Outcomes
PLATO
ATLAS-2 Long-term DAPT
DAPT Trial
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)